Alphatec (ATEC) Projected to Post Quarterly Earnings on Thursday

Alphatec (NASDAQ:ATEC - Get Free Report) is projected to release its Q2 2025 earnings data after the market closes on Thursday, July 31st. Analysts expect Alphatec to post earnings of ($0.06) per share and revenue of $178.85 million for the quarter. Alphatec has set its FY 2025 guidance at EPS.

Alphatec (NASDAQ:ATEC - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.23). Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 25.77%. The firm had revenue of $169.18 million during the quarter, compared to the consensus estimate of $167.57 million. During the same period in the previous year, the company posted ($0.34) earnings per share. The company's revenue for the quarter was up 22.2% on a year-over-year basis. On average, analysts expect Alphatec to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Alphatec Stock Up 1.0%

ATEC stock traded up $0.11 during trading on Friday, reaching $10.82. The stock had a trading volume of 857,795 shares, compared to its average volume of 1,440,822. Alphatec has a one year low of $4.88 and a one year high of $13.14. The company's 50 day moving average is $11.49 and its two-hundred day moving average is $11.11. The company has a market capitalization of $1.58 billion, a price-to-earnings ratio of -9.41 and a beta of 1.05.

Insider Activity at Alphatec

In related news, Director Karen K. Mcginnis sold 3,963 shares of the company's stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $12.11, for a total transaction of $47,991.93. Following the sale, the director directly owned 68,709 shares in the company, valued at approximately $832,065.99. This represents a 5.45% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Craig E. Hunsaker sold 13,878 shares of the company's stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $12.36, for a total transaction of $171,532.08. Following the sale, the executive vice president owned 1,450,018 shares in the company, valued at $17,922,222.48. The trade was a 0.95% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 299,547 shares of company stock worth $3,698,956. 20.90% of the stock is owned by corporate insiders.

Institutional Trading of Alphatec

A number of institutional investors have recently modified their holdings of ATEC. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Alphatec by 18.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 265,907 shares of the medical technology company's stock valued at $2,696,000 after purchasing an additional 41,264 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Alphatec in the first quarter worth $257,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Alphatec by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 74,005 shares of the medical technology company's stock worth $750,000 after buying an additional 3,196 shares in the last quarter. 66.35% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have issued reports on ATEC. Piper Sandler reaffirmed an "overweight" rating and issued a $15.00 price objective (up from $13.00) on shares of Alphatec in a research report on Friday, May 2nd. Needham & Company LLC reiterated a "buy" rating and issued a $16.00 target price on shares of Alphatec in a research note on Friday, May 2nd. HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of Alphatec in a research note on Monday, April 14th. Finally, Lake Street Capital upgraded shares of Alphatec to a "buy" rating and set a $18.00 target price on the stock in a research note on Monday, June 16th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $18.13.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.